Capital injection advances Rockeby's marketing plans
14 September, 2004 by Melissa TrudingerRockeby Biomed (ASX:RBY) has secured AUD$3 million from institutional and high net worth investors including current investors Queensland Investment Corporation and Thorney Holdings, which will both increase their holdings to become substantial shareholders.
Biology's central dogma goes out with the junk
14 September, 2004 by Graeme O'NeillJohn Mattick, director of the Institute for Molecular Biosciences at the University of Queensland, has told an international RNAi conference that biology's central dogma is wrong -- at least as it applies to higher organisms.
Bone upbeat after trial results
13 September, 2004 by Renate KrelleThe ambitions of Bone Medical (ASX:BNE) to bring the first oral version of osteoporosis drug calcitonin to the world market moved closer today, when the company announced encouraging results from a Phase I/IIa study of its lead candidate BN002.
Clients, kudos for Genetic Solutions
13 September, 2004 by Staff WritersBrisbane-based biotech Genetic Solutions has earned a new client and an accolade at the 2004 Premier of Queensland Smart Awards.
Peptech, Genera rumours premature
13 September, 2004 by Renate KrelleReports of Peptech's (ASX:PTD) impending takeover of tiny DNA-analysis company Genera Biosystems are premature, according the heads of both companies.
Ventracor starts global trial with implant in Perth
13 September, 2004 by Staff WritersVentracor (ASX:VCR) has begun a global trial of its VentrAssist device, with the implant of a patient suffering congestive heart failure at Royal Perth Hospital.
In brief: ResMed, Genesis, Genepharm, EG Capital
10 September, 2004 by Staff WritersSleep disorder specialist company ResMed (ASX:RMD) has promoted Kieran Gallahue from president and American chief operating officer to president of ResMed Global.
Healthcare leads rise in European venture capital funding
10 September, 2004 by Staff WritersEuropean venture-capital investment rose 10 per cent in the second quarter of this year over the first quarter to 967.3 million euros, driven by more funding for healthcare, including biopharmaceutical and medical-device companies
Solbec trial patients ask for more drug
09 September, 2004 by Melissa TrudingerEarly results from Solbec Pharmaceutical's (ASX: SBP) Phase I clinical trial to test the safety and tolerability of its glycoalkaloid-based anti-cancer drug SBP002 in patients with advanced mesothelioma and melanoma have been unexpectedly good, with a number of the patients requesting to continue on the drug after the trial ended.
Cochlear pioneer wins PM's science prize
08 September, 2004 by Melissa TrudingerThe inventor of the cochlear implant, Prof Graeme Clark, will use the AUD$300,000 cheque from the 2004 Prime Minister's Science Prize he was awarded this week to establish a $6 million professorial chair in medical bionics at his Bionic Ear Institute in Melbourne.
Nucleonics challenges Benitec-CSIRO RNAi patent
08 September, 2004 by Graeme O'NeillPennsylvanian anti-viral therapeutics developer Nucleonics has opened a new front, on Australian soil, in its battle with Brisbane biotech Benitec (ASX:BLT) and Australia’s national research agency, CSIRO, over ownership of key patents for the revolutionary gene-silencing technology called RNA interference (RNAi).
Cattle ID technology awarded
07 September, 2004 by Iain ScottA DNA tag for livestock -- a joint venture development between Brisbane biotechnology company Genetic Solutions and livestock management company Allflex -- has won recognition at the 2004 Premier of Queensland Smart Awards.
GroPep outlines commitment to R&D
07 September, 2004 by Melissa TrudingerTwo years ago, GroPep (ASX:GRO) was in trouble, badly burned and without a CEO after an ill-advised acquisition of Biotech Australia. Now, it looks like a different company -- profitable, and turning its attention towards its biopharmaceutical development projects after a successful turn-around in its fortunes.
Call for implant tracking system
07 September, 2004 by Melissa TrudingerThe Therapeutic Goods Administration has heard renewed calls for a national system for tracking the safety of critical implants and devices.
In brief: BresaGen, Epitan
06 September, 2004 by Melissa TrudingerThe company created by the merger between BresaGen's US-based stem cell therapy business and the San Diego based company Cythera has merged again with Novocell, a Californian company commercialising encapsulated cell technology for the treatment of diabetes and other diseases.
